The Temporary Spur Stent System comprises a patented retrievable stent system. Credit: Business Wire.

Reflow Medical has received breakthrough device designation for its Temporary Spur Stent System from the US Food and Drug Administration (FDA).

The retrievable stent technology is intended to treat below-the-knee (BTK) peripheral artery disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Temporary Spur Stent System comprises a patented retrievable stent system. It features a series of radially expandable spikes to create numerous pathways.

These pathways will assist in delivering antiproliferative drugs and ensure increased uptake into the vessel wall and also facilitate acute luminal gain, the company claims.

Reflow Medical CEO Isa Rizk said: “We are extremely grateful to the FDA for their expedited designation of the Temporary Spur Stent System as a Breakthrough Device.

“We plan to take full advantage of the Program’s benefits, accelerating our efforts towards meeting the requirements of the review process as we advance this novel technology, with the goal of improving the lives of patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The breakthrough devices programme aims towards offering patients and health care providers timely access to medical devices that give effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Currently, the Temporary Spur Stent System is not approved for sale and can be used only for an investigational purpose.

The company, in its press statement, said that based on the Spur technology platform it intends to develop in other clinical areas.

Based in California, Reflow develops various products to treat cardiovascular disease.